Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Veronica V Rezelj

Showing results (11-20 of 29) with videos related to

Pageof 3
Sort By:
The FEBS Journal|April 17, 2021
Host PDZ-containing proteins targeted by SARS-CoV-2Célia Caillet-Saguy, Fabien Durbesson, Veronica V Rezelj, et al.
Journal of Virology|July 5, 2019
Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated <i>In Vivo</i> and Have Compromised TransmissibilityLucía Carrau, Veronica V Rezelj, María G Noval, et al.
Human Vaccines & Immunotherapeutics|January 27, 2025
Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trialJelena Tica, Veronica V Rezelj, Benoit Baron, et al.
Plos Pathogens|February 8, 2021
Defective viral genomes from chikungunya virus are broad-spectrum antivirals and prevent virus dissemination in mosquitoesLaura I Levi, Veronica V Rezelj, Annabelle Henrion-Lacritick, et al.
Scientific Reports|August 7, 2023
A conformational rearrangement of the SARS-CoV-2 host protein sigma-1 is required for antiviral activity: insights from a combined in-silico/in-vitro approachFrancesca Serena Abatematteo, Pietro Delre, Ivan Mercurio, et al.
Human Vaccines & Immunotherapeutics|August 14, 2025
Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancyGloria Aguilar, Gabriela Tapia-Calle, Cynthia Robinson, et al.
Vaccines|October 26, 2024
Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical TrialVeronica V Rezelj, Fred Paddenburg, Marie Enajite Diegbe, et al.
Ebiomedicine|June 15, 2025
Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trialNina Hertoghs, Sanne Roels, Matthias Brückner, et al.
Journal of Virology|April 27, 2018
Interferon-Stimulated Gene (ISG)-Expression Screening Reveals the Specific Antibunyaviral Activity of ISG20Junjie Feng, Arthur Wickenhagen, Matthew L Turnbull, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2021
Phospholipidosis is a shared mechanism underlying the <i>in vitro</i> antiviral activity of many repurposed drugs against SARS-CoV-2Tia A Tummino, Veronica V Rezelj, Benoit Fischer, et al.
Pageof 3

Showing results (11-20 of 29) with videos related to

Sort By:
Pageof 3
The FEBS Journal|April 17, 2021
Host PDZ-containing proteins targeted by SARS-CoV-2Célia Caillet-Saguy, Fabien Durbesson, Veronica V Rezelj, et al.
Journal of Virology|July 5, 2019
Chikungunya Virus Vaccine Candidates with Decreased Mutational Robustness Are Attenuated <i>In Vivo</i> and Have Compromised TransmissibilityLucía Carrau, Veronica V Rezelj, María G Noval, et al.
Human Vaccines & Immunotherapeutics|January 27, 2025
Safety and immunogenicity of Ad26.COV2.S in adolescents: Phase 2 randomized clinical trialJelena Tica, Veronica V Rezelj, Benoit Baron, et al.
Plos Pathogens|February 8, 2021
Defective viral genomes from chikungunya virus are broad-spectrum antivirals and prevent virus dissemination in mosquitoesLaura I Levi, Veronica V Rezelj, Annabelle Henrion-Lacritick, et al.
Scientific Reports|August 7, 2023
A conformational rearrangement of the SARS-CoV-2 host protein sigma-1 is required for antiviral activity: insights from a combined in-silico/in-vitro approachFrancesca Serena Abatematteo, Pietro Delre, Ivan Mercurio, et al.
Human Vaccines & Immunotherapeutics|August 14, 2025
Safety, immunogenicity and pregnancy outcomes in mothers and infants after vaccination with an adenovirus-vector COVID-19 vaccine during pregnancyGloria Aguilar, Gabriela Tapia-Calle, Cynthia Robinson, et al.
Vaccines|October 26, 2024
Safety and Humoral Immunogenicity of Different Dose Levels of Ad26.COV2.S as a 2-Dose Regimen in COVID-19 Vaccine-Naïve Healthy Adults: A Phase 3 Randomized Clinical TrialVeronica V Rezelj, Fred Paddenburg, Marie Enajite Diegbe, et al.
Ebiomedicine|June 15, 2025
Vaccine-induced T cell responses correlate with reduced risk of severe COVID-19 in a placebo-controlled efficacy trialNina Hertoghs, Sanne Roels, Matthias Brückner, et al.
Journal of Virology|April 27, 2018
Interferon-Stimulated Gene (ISG)-Expression Screening Reveals the Specific Antibunyaviral Activity of ISG20Junjie Feng, Arthur Wickenhagen, Matthew L Turnbull, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2021
Phospholipidosis is a shared mechanism underlying the <i>in vitro</i> antiviral activity of many repurposed drugs against SARS-CoV-2Tia A Tummino, Veronica V Rezelj, Benoit Fischer, et al.
Pageof 3